Estrella Immunopharma (ESLA) Expected to Announce Quarterly Earnings on Wednesday

Estrella Immunopharma (NASDAQ:ESLA) is expected to announce its results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.0840) per share for the quarter.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.17. On average, analysts expect Estrella Immunopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Estrella Immunopharma Stock Down 8.1%

Shares of ESLA stock opened at $1.41 on Wednesday. The company has a market cap of $60.02 million, a price-to-earnings ratio of -4.02 and a beta of 0.97. Estrella Immunopharma has a 52 week low of $0.78 and a 52 week high of $3.15. The firm has a 50 day moving average of $1.34 and a 200-day moving average of $1.55.

Institutional Trading of Estrella Immunopharma

Several hedge funds have recently bought and sold shares of ESLA. Geode Capital Management LLC grew its position in Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after purchasing an additional 8,318 shares during the period. Renaissance Technologies LLC grew its position in Estrella Immunopharma by 1,045.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock valued at $191,000 after purchasing an additional 111,779 shares during the period. State Street Corp grew its position in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after purchasing an additional 20,900 shares during the period. Marshall Wace LLP acquired a new stake in Estrella Immunopharma in the 4th quarter valued at $88,000. Finally, Quadrature Capital Ltd acquired a new stake in Estrella Immunopharma in the 4th quarter valued at $43,000. Institutional investors and hedge funds own 0.35% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $8.00 price objective on shares of Estrella Immunopharma in a research report on Monday, February 9th. Weiss Ratings downgraded shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.